- Previous Close
0.0000 - Open
0.7497 - Bid 0.6471 x 40000
- Ask 0.7222 x 40000
- Day's Range
0.7497 - 0.7497 - 52 Week Range
0.4060 - 1.7310 - Volume
55 - Avg. Volume
498 - Market Cap (intraday)
36.975M - Beta (5Y Monthly) 1.97
- PE Ratio (TTM)
∞ - EPS (TTM)
0.0000 - Earnings Date Apr 21, 2025 - Apr 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
MustGrow Biologics Corp., an agricultural biotechnology company, focuses on development and commercialization of natural biological technologies and products from mustard seeds. It provides Biocontrol technology platform to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and others; treat unwanted plant growth for use in organic agriculture, and home and garden markets, as well as agriculture markets where glyphosate has been banned; and suppress sprouting, and treat disease and pathogen for storage and food preservation markets. The company also offers TerraMG, a mustard-derived soil biopesticide technology. In addition, it is developing TerraSante, an organic soil amendment and biofertility technology. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.
mustgrow.ca--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MGROF
View MorePerformance Overview: MGROF
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MGROF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MGROF
View MoreValuation Measures
Market Cap
34.14M
Enterprise Value
31.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.52
Price/Book (mrq)
15.69
Enterprise Value/Revenue
9.11
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.91%
Return on Assets (ttm)
2.63%
Return on Equity (ttm)
-8.43%
Revenue (ttm)
4.99M
Net Income Avi to Common (ttm)
-245.03k
Diluted EPS (ttm)
0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
3.57M
Total Debt/Equity (mrq)
15.37%
Levered Free Cash Flow (ttm)
450.44k